CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Cipro

ciprofloxacin· ingredient ciprofloxacinAntiinfectives· CIPROFLOXACIN HYDROCHLORIDE 250 mg/1; CIPROFLOXACIN HYDROCHLORIDE 500 mg/1; CIPROFLOXACIN HYDROCHLORIDE 750 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.11799
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per ML — the trend nobody else shows. 7 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other ciprofloxacin products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.

ProductNADAC / MLvs this
Ciprofloxacin$0.11799+$0.00000
Ciprofloxacin HCl Ophthalmic$1.62+$1.50
Ciprofloxacin Otic$6.85+$6.73
Ciprofloxacin and Dexamethasone$7.40+$7.28
CIPRO HC$34.87+$34.75
CILOXAN$74.28+$74.16

Medicare Part D coverage · CY2026

On 328 plan formularies · typical tier 1
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.